+

WO1998007415A3 - Procedes pour la prevention de la proliferation cellulaire et de la restenose - Google Patents

Procedes pour la prevention de la proliferation cellulaire et de la restenose Download PDF

Info

Publication number
WO1998007415A3
WO1998007415A3 PCT/EP1997/004503 EP9704503W WO9807415A3 WO 1998007415 A3 WO1998007415 A3 WO 1998007415A3 EP 9704503 W EP9704503 W EP 9704503W WO 9807415 A3 WO9807415 A3 WO 9807415A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prevention
restenosis
cellular proliferation
treatment
Prior art date
Application number
PCT/EP1997/004503
Other languages
English (en)
Other versions
WO1998007415A2 (fr
Inventor
Margaret Forney Prescott
Original Assignee
Ciba Geigy Ag
Margaret Forney Prescott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Margaret Forney Prescott filed Critical Ciba Geigy Ag
Priority to AU42055/97A priority Critical patent/AU4205597A/en
Publication of WO1998007415A2 publication Critical patent/WO1998007415A2/fr
Publication of WO1998007415A3 publication Critical patent/WO1998007415A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés pour la prévention et le traitement de maladies impliquant une prolifération cellulaire et une apoptose dysfonctionnelle. Ces procédés consistent à administrer des inhibiteurs de la protéine kinase C et leurs dérivés. En outre, l'invention traite de l'administration locale d'inhibiteurs de la protéine kinase C pour traiter la resténose et le cancer.
PCT/EP1997/004503 1996-08-20 1997-08-18 Procedes pour la prevention de la proliferation cellulaire et de la restenose WO1998007415A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42055/97A AU4205597A (en) 1996-08-20 1997-08-18 Methods for prevention of cellular proliferation and restenosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2421996P 1996-08-20 1996-08-20
US60/024,219 1996-08-20
US2507296P 1996-08-30 1996-08-30
US60/025,072 1996-08-30

Publications (2)

Publication Number Publication Date
WO1998007415A2 WO1998007415A2 (fr) 1998-02-26
WO1998007415A3 true WO1998007415A3 (fr) 1998-05-07

Family

ID=26698189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/004503 WO1998007415A2 (fr) 1996-08-20 1997-08-18 Procedes pour la prevention de la proliferation cellulaire et de la restenose

Country Status (3)

Country Link
AU (1) AU4205597A (fr)
ID (1) ID18301A (fr)
WO (1) WO1998007415A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123996B2 (en) 2006-09-13 2018-11-13 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190869B1 (en) 1999-10-26 2001-02-20 Isis Pharmaceuticals, Inc. Antisense inhibition of protein kinase C-theta expression
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
KR100926194B1 (ko) 2001-10-30 2009-11-09 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의스타우로스포린 유도체
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2702993B1 (fr) 2006-09-13 2017-12-06 Elixir Medical Corporation Composés de lactone macrocyclique et procédés pour leur utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1993019203A1 (fr) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Modulation par oligonucleotide de la proteine kinase c
EP0588762A1 (fr) * 1992-08-31 1994-03-23 Ciba-Geigy Ag Utilisation de dérivés de pyrimidine comme inhibiteurs de la protéine kinase C et comme médicaments contre les tumeurs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO1993019203A1 (fr) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Modulation par oligonucleotide de la proteine kinase c
EP0588762A1 (fr) * 1992-08-31 1994-03-23 Ciba-Geigy Ag Utilisation de dérivés de pyrimidine comme inhibiteurs de la protéine kinase C et comme médicaments contre les tumeurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10123996B2 (en) 2006-09-13 2018-11-13 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use

Also Published As

Publication number Publication date
AU4205597A (en) 1998-03-06
ID18301A (id) 1998-02-26
WO1998007415A2 (fr) 1998-02-26

Similar Documents

Publication Publication Date Title
WO1999057117A3 (fr) Derives indoliques et leur utilisation pour le traitement de maladies malignes et autres induites par des proliferations cellulaires pathologiques
WO2001028494A3 (fr) Derives nordihydroguaiartiques destines a une utilisation dans le traitement de tumeurs
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
MY120841A (en) Methods of inducing cancer cell death and tumor regression
EP1374875A3 (fr) Compositions pharmaceutiques à base d'arsenic pour le traitement du syndrome myelodysplastique
WO1999015167A3 (fr) Utilisation de limonoides et de flavonoides d'agrumes et de tocotrienols pour le traitement du cancer
HK1048813A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for their use.
WO2000008202A3 (fr) Modulateurs 3-methylidenyl-2-indolinone de proteine kinase
GR3036188T3 (en) Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
WO2002028832A3 (fr) Compositions de diindolylmethane et de diindolylmethane c-substitue et procedes de traitement de cancers multiples
AU3400297A (en) Gm-csf administration for the treatment and prevention of recurrence of brain tumors
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
PL373912A1 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU2508597A (en) Drug for the treatment of tumours
NZ524936A (en) Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO1998007415A3 (fr) Procedes pour la prevention de la proliferation cellulaire et de la restenose
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
WO2001083450A3 (fr) Derives d'acide acetique (2-oxindole-3-ylidenyl) et leur utilisation comme inhibiteurs de la proteine kinase
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
WO1998003518A3 (fr) Nouveaux complexes de bis-platine comportant des derives de polymethylene, utilises en tant que ligands dotes d'une activite antitumorale
CA2298820A1 (fr) Utilisation de 1,3,4,6-tetrahydroxy-helianthrone et de ses derives dans le traitement photodynamique et certains nouveaux derives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998510405

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载